Kassem A S, Zaher S R, Abou Shleib H, el-Kholy A G, Madkour A A, Kaplan E L
Department of Pediatrics, Faculty of Medicine, Alexandria University, Egypt.
Pediatrics. 1996 Jun;97(6 Pt 2):992-5.
This prospective study was aimed at answering two important questions: 1) Is a biweekly schedule of 1.2 million U intramuscular benzathine penicillin G (BPG) superior to a 4-week one in the prevention of upper respiratory Group A beta-hemolytic streptococcal (GABHS) infections and rheumatic fever (RF) recurrences? 2) Is there a difference in the bioavailability of BPG obtained from different manufacturers?
Three hundred sixty rheumatic patients aged 4 to 20 years were randomly assigned to either a biweekly (190 patients) or 4-week (160 patients) BPG prophylactic schedule and were followed-up monthly for 2 years by clinical examination, throat swab culture for GABHS and measurement of antistreptolysin O titer to detect GABHS infection and/or recurrences of RF (according to revised Jones' Criteria). Thereafter, 34 rheumatic subjects, aged 8 to 16 years were randomly assigned to receive a 4-week injection of 1.2 million U of either a locally manufactured BPG brand (22 patients) or an imported one (12 patients). Sera of all patients were tested for penicillin level by plate diffusion method on days 1, 2, 3, 4, 5, 6, 7, 14, 21, and 28 after the intramuscular injection of BPG.
The GABHS infection rate was found to be 0.2% and 0.3% for patients on the biweekly and 4-week BPG schedules, respectively, with no significant differences between them. However, the RF recurrence rate/patient/year for the 4-week schedule patients (0.12) was double that for the biweekly schedule ones (0.06). Estimation of the bioavailability of the two different brands of BPG demonstrated a difference in their pharmacokinetics and a decrease in the serum penicillin concentration below the minimum inhibitory concentration 3 weeks after the injection of either brand.
Although a biweekly schedule may not be superior in preventing upper respiratory GABHS infection, it may play a role in preventing the sequelae of such infections. The short duration of penicillinemia explains the superiority of the 2-week schedule in RF prophylais. The difference in the pharmacokinetics of penicillin brands might contribute to the high recurrence rate of RF reported in Egypt.
这项前瞻性研究旨在回答两个重要问题:1)每两周注射120万单位苄星青霉素G(BPG)预防上呼吸道A组β溶血性链球菌(GABHS)感染和风湿热(RF)复发,是否优于四周注射一次?2)不同厂家生产的BPG生物利用度是否存在差异?
360名4至20岁的风湿热患者被随机分为两组,一组每两周注射一次BPG(190例),另一组每四周注射一次(160例),并通过临床检查、GABHS咽拭子培养以及抗链球菌溶血素O滴度测定进行为期2年的每月随访,以检测GABHS感染和/或RF复发(根据修订的琼斯标准)。此后,34名8至16岁的风湿热受试者被随机分配接受为期四周的120万单位BPG注射,其中22例使用本地生产的BPG品牌,12例使用进口品牌。在肌肉注射BPG后的第1、2、3、4、5、6、7、14、_21_和28天,采用平板扩散法检测所有患者血清中的青霉素水平。
每两周注射一次BPG和每四周注射一次BPG的患者,GABHS感染率分别为0.2%和0.3%,两者之间无显著差异。然而,每四周注射一次BPG的患者每年的RF复发率(0.12)是每两周注射一次患者(0.06)的两倍。对两种不同品牌BPG生物利用度的评估显示,它们的药代动力学存在差异,且在注射任何一种品牌后3周,血清青霉素浓度均降至最低抑菌浓度以下。
虽然每两周注射一次在预防上呼吸道GABHS感染方面可能并不优于四周注射一次,但在预防此类感染的后遗症方面可能发挥作用。青霉素血症持续时间短解释了两周注射方案在预防RF方面的优势。青霉素品牌药代动力学的差异可能是埃及报道的RF高复发率的原因之一。